DABIGATRAN ETEXILATE EG LABO 150 mg, hard capsule 60 capsules
Active ingredients: DABIGATRAN ÉTEXILATE, MÉSILATE DE DABIGATRAN ÉTEXILATE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DABIGATRAN ETEXILATE EG LABO 150 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 6 plaquette(s) prédécoupées aluminium OPA : polyamide orienté PVC de 10 gélule(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62154642CIP73026127CIP133400930261279Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DABIGATRAN ÉTEXILATEgélule | 150 mg · une gélule | FT |
| MÉSILATE DE DABIGATRAN ÉTEXILATEgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: DABIGATRAN ETEXILATE (MESILATE DE) équivalant à DABIGATRAN ETEXILATE 150 mg - PRADAXA 150 mg, gélule